cvs9yt, I went to the video and watched it from 4/17/14, and Cramer said he was not going to say anything negative because MNKD is a cult stock and it will overload his twitter account the next four days telling him what a jerk he is. He did mention in a goofy way the small device. He said he does not know how big the device is going to be (meaning, I think, he does not know how successful Afrezza is going to be). He said he is critical and remains skeptical. Ja und. He is skeptical, because AF of some short buddy told him to be skeptical.
Don't get fumed over Cramer's ignorance. Several years ago when I owned SSYS at much lower prices, someone called in about it. He knew nothing but said don't buy. Maybe 60 points higher he loved SSYS.
Since the FDA staff people at the AdCom did not understand the diabetic's blood sugar control problem other than through their A1c benchmark until the AdCom panel of doctors/scientists and mostly the diabetics' testimonials explained it to them, how can we expect a momentum stock jock/yell king, Cramer, to have any idea what he might think if he understood the blood sugar control problem. No one has explained it to him, and he would not understand the chemical mechanism anyway. Cramer will love Afrezza in a year, and wear a post-it to tell all how wrong he has been. Of course that is not good enough, but he did not know anything about SSYS at 25 and still #$%$ on it in his lightning round. I know he has loved it in the past 12 months or more around 100.
turk_74, your various reasoned replies confused me, and I think I figured out why. In your three different replies, you mixed staff and panel in one of your replies(specifically the 2nd reply timewise). I believe you corrected your meaning with your third post reply in this thread. Just for completeness in order that I might have it clear in my reading: When I think staff, you meant the staff people who work for the FDA who were sitting there at the table. When I think panel, you meant the various invited doctors/scientists who were also sitting at the tables, and in addition the people who voted 13-1 and 14--0 in favor of Type 1 and Type 2, respectively. If I am wrong, please correct me.
seagate48, you can buy a DVD or watch the video of the entire MNKD AdCom by going to fdalive . You can guess the rest of the suffix for fdalive, but I have to write it this way for Yahoo not to delete the post. Their autodeleter software appears to have eaten my prior post to you when I used the word period between the term and the suffix.
new21yroldinvestor, you did get the lying use, as in reclining, right. But mercy, are you aware the tenses in all your other sentences are totally incorrect? You need to hit the books on the use of adverbs too. In your college are you still able to take some remedial grammar course or courses? In your effort to teach people the correct use of to lie instead of to lay in the reclining sense, you have exposed your flank in other areas of grammar. You sound like someone who wants to learn, and you have some learning to do in English. My degrees have nothing to do with English, but I had a good grammar teacher in middle school. I don't normally rag on the often poorly written posts on Yahoo, but when someone wants to teach others, perhaps that person can learn something too. Maybe English is not your mother tongue, i.e., first language.
jstokcton, why don't you read the S1 that Dance has on file with the SEC since about April 9th? It has all the details and curves you need to know and understand. It is clear from their PK information, Dance looks just like the insulin analogs that are on the market today and the past many years -- long tails and all to get out of the system and cause hypos. They show their curves to look just like Humalog. Is everyone here so lazy, or do they just not know how to do the simplest research. The device information is also in the S1 including who makes it for Dance and how it functions (with batteries it appears), etc., etc.
If Dance really does an IPO, it is just to get some of the founders and investors out with some money in their pockets. I have already posted some days ago that Dance should go the Kickstarter route instead of an IPO.
Almost everyone knows SA authors are compensated for their writings. Why the question? This fellow knows the more controversy he raises among readers, the more money he will make. Is this really news to Yahoo message board readers. SA has posted the rates it pays. I have read it before on the SA site. Of course he could be getting paid by someone else to write too. Just double dipping I suppose.
When I read the SEC filing, it appeared Dance would be better off using Kickstarter instead of trying to do an IPO. Their insulin curves look like Humalog, which is one that Afrezza will replace.
broad_and_south, that is just boiler plate. Suit your own judgment, but over 50% control in the HSR law is a merger. Note the acquired party in Al Mann's case is Mannkind. If Al did not own 50% or more of MNKD before, he has FTC approval under HSR to own it now.
broad_and_south, I am not certain, but I read a few days ago Al Mann has 44% of MNKD shares currently. I read over the Hart Scott Rodino law(HSR), and it appears if Al wants to have more than 50% ownership by purchasing more common stock, the Hart Scott Rodino disclosure to the FTC is required. The details of Al's disclosure will not be disclosed by the FTC. I think all that happened was Al got the FTC ok to purchase more stock to put him over 50% control (in the HSR meaning) of MNKD. He may have done it Monday. If Al already owned 50% of MNKD stock, then I suppose I will have been wrong in my conclusion.
daduke38, my thought is mrbillyray sold too much of his mnkd, and needs to get 'em back. He seems negative to me now.
carlpunti, I watched the AdCom video (yes, I paid the $200.). I also read the panel member log link that the FDA provided. You can find it too and read all the voting panel members as well as the Novo guy, Mads something, who was a non-voting panel member.
carlpunti and gmanwicksy, there were 15 panel members, but Dr. Swenson from Seattle had to leave early just before the vote. I presume he needed to catch a plane or some such thing. Only 14 panel members remained to vote. That is how the 14 panel members who voted are accounted for. That accounts for the total of 27 of 28 total votes for Type 1 and Type 2 by the panel members who remained. carlpunti, I have not read many of your posts, but it is clear that gmanwicksy is quite ignorant of many things in medicine as well as English spelling and grammar. gmanwicksy, I don't know if you are dumb or smart, but you are certainly ignorant.
uncle.bigs, no need for you to lie to people. Lucky for diabetics Afrezza brings down the mealtime blood sugar spikes into the normal blood sugar zone without bringing the blood sugar down out of the zone that would cause hypoglycemia. Afrezza's ultra fast acting insulin's impact is to avoid the hyperglycemia spikes and levels while bringing the blood sugar into the zone and not into the hypoglycemia area of too low blood sugar.
afrezzauser, these messages get lost in the posting clutter. If you want to get this letter writing campaign message out, I suggest you post a separate message as a new topic instead of a reply to some other post. At least that way it has a higher probability of being seen by the people who are scanning the main posted topics.
If anyone wants the April 3 Citi analyst NG storage analysis and report, do the instructions like in my post above, but post number 183357 is the one you want to get to the link for the latest Citi report. Page 8 is the matrix you want to see in addition to words on pages 1 and 2.
seyhey44, you can be nice about it if you want, but the Indian reviewer, Lokesh Jain, did not understand the control system problem that diabetes and the blood sugar range problem are for the body. If I had been on the AdCom panel, I would have fallen out of my chair or slumped under the table. I would have known by Jain's charts and words that what I have here is a reviewer who does not even understand the control system problem. I would have thought, how is this possible. We have people reviewing the data who do not understand what the data means or even what the problems are with diabetes. It was and is stunning!
dankaeck, this come from a fellow at cwei who used to post all the time on the Yahoo board under handle robry825. You can read what he wrote on the clayton williams blog on his calculations for current storage levels as of April 4. He says below it would be hard to believe the amount is even 700 Bcf at this time. This guy's track record is very good.
Coming from Robry gives that number a lot of credibility. If the EIA numbers are that far off, shoulder season price weakness may not happen this year.
......SEASON-END STORAGE LEVEL: I have been dreading posting on this (and promised myself that I would not until
......we were out of withdrawal season) but the producing-region-salt-skew has persisted... as storage in salt-domes
......has been far-less hit than conventional storage... and mathematically, I think the validity of the EIA's data reporting,
......collecting, and estimating process comes under question.
......The skew presently estimates out (in the EIA-weighted model) to an accumulated 239 BCF (EIA weighted model
......has 835 BCF in storage, Capacity/Gas-flow modeling 596 BCF in storage, and looking at the publicly-released storage
......levels (by operators such as PG&E, SOCAL, ANR Pipeline, Dominion, and Columbia Gas Transmission) the major
......players are far below the percentage-draw implied by the EIA, and the differences are so large that it is nerely impossible
......to take the EIA estimate as serious.
......So (in my own conclusions) storage at 835 is a statistical near-impossibility (based upon non-EIA storage reporting).
......Last years 3834 BCF 11/08/13 peak is therefore discounted, with the actual peak and trough being much more likely near
......the Capacity/Gas-Flow models 3470 BCF (11/08/13) and 591 BCF (03/31/14) output. It is extremely unlikely that storage
......is even above 700 BCF at this point.
jhnnylikes, until good education about Afrezza's mechanism and workings in the body are well understood by primary care physicians, endocrinologists will Need to be involved in type 1 and type 2 patient readiness. Sharp PCPs will get educated & involved to help their diabetic patients, but other PCPs will need to get an endocrinologist to lead the way for them. Primary care physicians are frayed at both ends these days, and need drugs that are simple to prescribe and use. I think PCPs will need plenty of education and sitting with some endo doctors to get it right for their patients, or they can send diabetics to endos.
sugarman005, I have read many of your posts in the past several months. It appears to me you work in some medical field, but my memory is not clear on this. Am I correct? I do not need details.
brheavy, how stupid of me. If anyone wants to see your replies to tabsomem and noquickgame but minus their questions, they can simply click on your handle, brheavy, and your replies are there for anyone to view. Sorry about the post I just wrote to you about posting your two replies to those two handles.